Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus

E. Scott Monrad, A. Matsumori, J. C. Murphy, J. G. Fox, C. S. Crumpacker, W. H. Abelmann

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

To explain the progression from infectious viral myocarditis to congestive cardiomyopathy an infection/immune hypothesis has been proposed stating that the primary viral process incites an excessive or disordered immunologic response against the myocardium. To test whether one form of immunosuppressive therapy might ameliorate this process, we used cyclosporine in a murine preparation of infectious myocarditis (encephalomyocarditis [EMC] virus), which has been shown to result in a congestive cardiomyopathy pathologically similar to that seen in man. Eight-week-old male DBA-2 mice were infected with EMC virus and randomized to a treatment or control group. Cyclosporine (25 mg/kg/day) was administered subcutaneously for 3 weeks, starting (1) at one week after infection during viral replication, and (2) at 3 weeks after infection, after the period of active viral replication. In mice treated during viral replication there was a significantly higher mortality rate compared with that of control mice (15/21 vs 9/29, p = .01). There was no evident reduction in myocardial pathology (inflammation, necrosis, or calcification) in the treated compared with the control groups. In mice treated after the period of viral replication, there was no improvement in mortality (8/22 vs 2/19, NS) compared with control. Treated mice showed no reduction in myocardial histopathologic lesions. Furthermore, treated mice had significantly greater heart weight/body weight ratios (1.3 ± 0.4% vs 1.0 ± 0.3%, p < .005), lung weight/body weight ratios (1.1 ± 0.5% vs 0.8 ± 0.3%, p < .05), and liver weight/body weight ratios (6.0 ± 0.8% vs 5.4 ± 0.6%, p < .005) than control mice, suggesting more severe myocardial failure. Thus, the use of immunosuppressive therapy with cyclosporine in this murine preparation of acute viral myocarditis was associated with greater mortality when administered early in the illness, and greater myocardial failure when administered during the early recovery period, without evident reduction in pathologic indexes of myocardial injury to suggest possible longer term benefit. Clinical trials of cyclosporine therapy for inflammatory myocarditis secondary to an acute viral infection should be carried out with great caution and only in the setting of a carefully controlled clinical trial.

Original languageEnglish (US)
Pages (from-to)1058-1064
Number of pages7
JournalCirculation
Volume73
Issue number5
StatePublished - 1986
Externally publishedYes

Fingerprint

Encephalomyocarditis virus
Myocarditis
Cyclosporine
Body Weight
Dilated Cardiomyopathy
Virus Diseases
Immunosuppressive Agents
Weights and Measures
Mortality
Therapeutics
Heart Failure
Control Groups
Inbred DBA Mouse
Controlled Clinical Trials
Infection
Myocardium
Necrosis
Clinical Trials
Pathology
Inflammation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Monrad, E. S., Matsumori, A., Murphy, J. C., Fox, J. G., Crumpacker, C. S., & Abelmann, W. H. (1986). Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. Circulation, 73(5), 1058-1064.

Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. / Monrad, E. Scott; Matsumori, A.; Murphy, J. C.; Fox, J. G.; Crumpacker, C. S.; Abelmann, W. H.

In: Circulation, Vol. 73, No. 5, 1986, p. 1058-1064.

Research output: Contribution to journalArticle

Monrad, ES, Matsumori, A, Murphy, JC, Fox, JG, Crumpacker, CS & Abelmann, WH 1986, 'Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus', Circulation, vol. 73, no. 5, pp. 1058-1064.
Monrad ES, Matsumori A, Murphy JC, Fox JG, Crumpacker CS, Abelmann WH. Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. Circulation. 1986;73(5):1058-1064.
Monrad, E. Scott ; Matsumori, A. ; Murphy, J. C. ; Fox, J. G. ; Crumpacker, C. S. ; Abelmann, W. H. / Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. In: Circulation. 1986 ; Vol. 73, No. 5. pp. 1058-1064.
@article{b750beafc8b74911a44454bf2b74d394,
title = "Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus",
abstract = "To explain the progression from infectious viral myocarditis to congestive cardiomyopathy an infection/immune hypothesis has been proposed stating that the primary viral process incites an excessive or disordered immunologic response against the myocardium. To test whether one form of immunosuppressive therapy might ameliorate this process, we used cyclosporine in a murine preparation of infectious myocarditis (encephalomyocarditis [EMC] virus), which has been shown to result in a congestive cardiomyopathy pathologically similar to that seen in man. Eight-week-old male DBA-2 mice were infected with EMC virus and randomized to a treatment or control group. Cyclosporine (25 mg/kg/day) was administered subcutaneously for 3 weeks, starting (1) at one week after infection during viral replication, and (2) at 3 weeks after infection, after the period of active viral replication. In mice treated during viral replication there was a significantly higher mortality rate compared with that of control mice (15/21 vs 9/29, p = .01). There was no evident reduction in myocardial pathology (inflammation, necrosis, or calcification) in the treated compared with the control groups. In mice treated after the period of viral replication, there was no improvement in mortality (8/22 vs 2/19, NS) compared with control. Treated mice showed no reduction in myocardial histopathologic lesions. Furthermore, treated mice had significantly greater heart weight/body weight ratios (1.3 ± 0.4{\%} vs 1.0 ± 0.3{\%}, p < .005), lung weight/body weight ratios (1.1 ± 0.5{\%} vs 0.8 ± 0.3{\%}, p < .05), and liver weight/body weight ratios (6.0 ± 0.8{\%} vs 5.4 ± 0.6{\%}, p < .005) than control mice, suggesting more severe myocardial failure. Thus, the use of immunosuppressive therapy with cyclosporine in this murine preparation of acute viral myocarditis was associated with greater mortality when administered early in the illness, and greater myocardial failure when administered during the early recovery period, without evident reduction in pathologic indexes of myocardial injury to suggest possible longer term benefit. Clinical trials of cyclosporine therapy for inflammatory myocarditis secondary to an acute viral infection should be carried out with great caution and only in the setting of a carefully controlled clinical trial.",
author = "Monrad, {E. Scott} and A. Matsumori and Murphy, {J. C.} and Fox, {J. G.} and Crumpacker, {C. S.} and Abelmann, {W. H.}",
year = "1986",
language = "English (US)",
volume = "73",
pages = "1058--1064",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus

AU - Monrad, E. Scott

AU - Matsumori, A.

AU - Murphy, J. C.

AU - Fox, J. G.

AU - Crumpacker, C. S.

AU - Abelmann, W. H.

PY - 1986

Y1 - 1986

N2 - To explain the progression from infectious viral myocarditis to congestive cardiomyopathy an infection/immune hypothesis has been proposed stating that the primary viral process incites an excessive or disordered immunologic response against the myocardium. To test whether one form of immunosuppressive therapy might ameliorate this process, we used cyclosporine in a murine preparation of infectious myocarditis (encephalomyocarditis [EMC] virus), which has been shown to result in a congestive cardiomyopathy pathologically similar to that seen in man. Eight-week-old male DBA-2 mice were infected with EMC virus and randomized to a treatment or control group. Cyclosporine (25 mg/kg/day) was administered subcutaneously for 3 weeks, starting (1) at one week after infection during viral replication, and (2) at 3 weeks after infection, after the period of active viral replication. In mice treated during viral replication there was a significantly higher mortality rate compared with that of control mice (15/21 vs 9/29, p = .01). There was no evident reduction in myocardial pathology (inflammation, necrosis, or calcification) in the treated compared with the control groups. In mice treated after the period of viral replication, there was no improvement in mortality (8/22 vs 2/19, NS) compared with control. Treated mice showed no reduction in myocardial histopathologic lesions. Furthermore, treated mice had significantly greater heart weight/body weight ratios (1.3 ± 0.4% vs 1.0 ± 0.3%, p < .005), lung weight/body weight ratios (1.1 ± 0.5% vs 0.8 ± 0.3%, p < .05), and liver weight/body weight ratios (6.0 ± 0.8% vs 5.4 ± 0.6%, p < .005) than control mice, suggesting more severe myocardial failure. Thus, the use of immunosuppressive therapy with cyclosporine in this murine preparation of acute viral myocarditis was associated with greater mortality when administered early in the illness, and greater myocardial failure when administered during the early recovery period, without evident reduction in pathologic indexes of myocardial injury to suggest possible longer term benefit. Clinical trials of cyclosporine therapy for inflammatory myocarditis secondary to an acute viral infection should be carried out with great caution and only in the setting of a carefully controlled clinical trial.

AB - To explain the progression from infectious viral myocarditis to congestive cardiomyopathy an infection/immune hypothesis has been proposed stating that the primary viral process incites an excessive or disordered immunologic response against the myocardium. To test whether one form of immunosuppressive therapy might ameliorate this process, we used cyclosporine in a murine preparation of infectious myocarditis (encephalomyocarditis [EMC] virus), which has been shown to result in a congestive cardiomyopathy pathologically similar to that seen in man. Eight-week-old male DBA-2 mice were infected with EMC virus and randomized to a treatment or control group. Cyclosporine (25 mg/kg/day) was administered subcutaneously for 3 weeks, starting (1) at one week after infection during viral replication, and (2) at 3 weeks after infection, after the period of active viral replication. In mice treated during viral replication there was a significantly higher mortality rate compared with that of control mice (15/21 vs 9/29, p = .01). There was no evident reduction in myocardial pathology (inflammation, necrosis, or calcification) in the treated compared with the control groups. In mice treated after the period of viral replication, there was no improvement in mortality (8/22 vs 2/19, NS) compared with control. Treated mice showed no reduction in myocardial histopathologic lesions. Furthermore, treated mice had significantly greater heart weight/body weight ratios (1.3 ± 0.4% vs 1.0 ± 0.3%, p < .005), lung weight/body weight ratios (1.1 ± 0.5% vs 0.8 ± 0.3%, p < .05), and liver weight/body weight ratios (6.0 ± 0.8% vs 5.4 ± 0.6%, p < .005) than control mice, suggesting more severe myocardial failure. Thus, the use of immunosuppressive therapy with cyclosporine in this murine preparation of acute viral myocarditis was associated with greater mortality when administered early in the illness, and greater myocardial failure when administered during the early recovery period, without evident reduction in pathologic indexes of myocardial injury to suggest possible longer term benefit. Clinical trials of cyclosporine therapy for inflammatory myocarditis secondary to an acute viral infection should be carried out with great caution and only in the setting of a carefully controlled clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=0022576432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022576432&partnerID=8YFLogxK

M3 - Article

C2 - 3698228

AN - SCOPUS:0022576432

VL - 73

SP - 1058

EP - 1064

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -